Modality
ADC
MOA
Anti-Aβ
Target
TNFα
Pathway
JAK/STAT
Crohn'sDravet
Development Pipeline
Preclinical
~May 2012
→ ~Aug 2013
Phase 1
~Nov 2013
→ ~Feb 2015
Phase 2
~May 2015
→ ~Aug 2016
Phase 3
~Nov 2016
→ ~Feb 2018
NDA/BLA
May 2018
→ Dec 2029
NDA/BLACurrent
NCT04663068
789 pts·Dravet
2022-01→2026-03·Completed
NCT03962231
881 pts·Crohn's
2018-05→2029-12·Recruiting
1,670 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-231w agoPh3 Readout· Dravet
2029-12-133.7y awayPh3 Readout· Crohn's
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
NDA/BLA
Recruit…
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2026-03-23 · 1w ago
Dravet
Ph3 Readout
2029-12-13 · 3.7y away
Crohn's
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04663068 | NDA/BLA | Dravet | Completed | 789 | CfB |
| NCT03962231 | NDA/BLA | Crohn's | Recruiting | 881 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα | |
| VKT-4052 | Viking Therapeutics | Phase 2/3 | TNFα |